Dr. Johannes Zuegg completed his PhD (Chemistry, Molecular Modelling) at the Technical University of Graz (Austria) and spent one year as a PostDoc at the University of Graz (Austria) doing protein crystallography. After migrating to Australia he was working on Molecular Dynamics simulations for 2.5 years at the John Curtin School of Medical Research at the Australian National University (Canberra), before joining Alchemia Inc., a small Bio-Tech company in Brisbane, as Molecular Modeller in Drug Development for 2 years. After a one year interruption as Computer Research Specialists at Griffith University (Brisbane), he rejoined Alchemia Inc. as Head of IT and Molecular Modelling for another 5 years. He joined the IMB and the Cooper Group in May 2009 as a Senior Research Officer working across the different drug design and development projects. Since 2015, Johannes is CO-ADD program coordinator for chemoinformatics and logistics.
Dr. Silver received her Ph.D. at Tufts University in Molecular Biology and Microbiology and did postdoctoral work on bacterial DNA replication at the Université de Genève, and on DNA replication biochemistry of bacteriophage T4 at NIH. In 1982, she joined Merck Research Laboratories (Rahway, NJ), where she worked for 21 years, conducting research and supervising groups involved in discovery efforts for new antibacterials in both natural products and chemical collections, support of chemical synthetic projects on improved antibacterials, pre-clinical evaluation of antibacterial drug candidates and the study of antibacterial resistance. She was involved in the discoveries of the first LpxC inhibitors and platensimycin. After taking early retirement from Merck in 2003, she established an independent consultancy (LL Silver Consulting, LLC) to the pharmaceutical industry in the area of antibacterial discovery and pre-clinical development. Throughout her career, she has authored significant research papers and reviews in the field of bacterial genetics, physiology, and biochemistry, as well as discovery and analysis of antibacterial agents. She is a member of the Editorial Board of Antimicrobial Agents and Chemotherapy and ACS Infectious Diseases, was a standing member of the NIH DDR Study Section, an ad hoc reviewer in other study sections, and has been a member of Scientific Advisory Boards of a number of biotechnology companies. She has spoken at and chaired numerous meetings focused on antibacterial discovery.
Joe Thomas is an associate on the Pew Charitable Trusts’ antibiotic resistance project. Joe conducts research and advocates for policies to help spur the discovery and development of urgently needed antibiotics. Prior to Pew, he worked at the London School of Economics and Political Science (LSE) studying the economics of rapid diagnostic device development and the use of web search data for modeling infectious diseases in developing countries. He has bachelor’s degrees in biology and political science from the University of Pittsburgh and an MSc from the LSE.